Join the Diabetes, Type 2 group to help and get support from people like you.
Diabetes, Type 2 News
Related terms: Noninsulin-dependent Diabetes, Type 2 Diabetes, Diabetes, Type 2
Muscle Ultrasound Can Detect Insulin Resistance
MONDAY, June 30, 2025 – Muscle ultrasound can detect insulin resistance and lower muscle mass, according to a study published online June 12 in the Journal of Ultrasound Medicine. Steven B. Soliman,...
Disparities Seen in Continuous Glucose Monitor Rx by Language Preference
FRIDAY, June 27, 2025 – For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language preference, with less access to CGM prescriptions...
ADA: Insulin Efsitora Noninferior to Glargine for Reducing HbA1c in Adults With Type 2 Diabetes
FRIDAY, June 27, 2025 – Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among adults with type 2...
Empagliflozin Has Kidney Protective Effects in Acute Myocardial Infarction
THURSDAY, June 26, 2025 – Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial infarction (MI),...
ADA: Weight Loss, Type 2 Diabetes Remission Up With Replacing Diet Drinks With Water
WEDNESDAY, June 25, 2025 – For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated with greater weight loss and T2D remission,...
ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes
WEDNESDAY, June 25, 2025 – The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early type 2 diabetes,...
Monthly Obesity Shot, MariTide, Shows Big Weight Loss in Trial
WEDNESDAY, June 25, 2025 — Alternatives to weekly injections of weight-loss drugs may on the way. A monthly dose of a new drug called MariTide helped participants in a phase 2 clinical trial shed a...
Trading Diet Sodas For Water Can Help Control Diabetes And Lose Weight
MONDAY, June 23, 2025 — Want to lose weight and reverse type 2 diabetes? Trade your diet soda for a tall glass of water, a new small-scale study argues. Women were more likely to drop pounds and see t...
ADA: Ecnoglutide Yields Superior, Sustained Reduction in Body Weight
MONDAY, June 23, 2025 – For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon like peptide 1 receptor agonist, ecnoglutide, yields a...
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
FRIDAY, June 20, 2025 – For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and cardiovascular event risks,...
DASH Diet for Diabetes With Low Sodium Reduces BP in Those With Diabetes
WEDNESDAY, June 18, 2025 – The Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) diet with lower sodium is tied to clinically meaningful blood pressure reduction in people with diabetes,...
Blood Pressure Diet Helps Type 2 Diabetics
TUESDAY, June 17, 2025 — A diet meant to lower blood pressure also can be effective in treating type 2 diabetes after a few tweaks, a new clinical trial indicates. The DASH (Dietary Approaches to S...
Most People Open To Sharing Smartwatch Health Data With Doctors
THURSDAY, June 12, 2025 — A person’s smartwatch can capture a lot of data about their health – and a new study says most folks are willing to share it with doctors. About 94% of people who wear smart...
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 – For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower than the percentages...
Real-World Results For GLP-1 Drugs Underwhelm, Study Says
WEDNESDAY, June 11, 2025 — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren’t as impressive as those promised by the drugs’ clinical trials, a new study says....
Further information
Related condition support groups
Related drug support groups
metformin, Ozempic, Victoza, Mounjaro, Lantus, semaglutide, Trulicity, glipizide, Rybelsus, view more... Jardiance, liraglutide, tirzepatide, Lantus Solostar, Humalog, Farxiga, Novolog, Janumet, insulin glargine, Januvia, Bydureon, insulin lispro, Tresiba, dulaglutide, Levemir, insulin degludec, Invokana, Glucophage, Humulin N